Drugs / MK-4830A
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03564691 | Jul 2018 → Sep 2025 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-4830A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03564691 ↗ |
| Route | Intravenous | “MK-4830A, a coformulation of MK-4830 800 mg + pembrolizumab 200 mg, will be administered IV Q3W.” NCT03564691 ↗ |